Abstract |
The clinical efficacy of vectrine ( erdosteine) was evaluated in the treatment of chronic bronchitis patients with hypersecretion during a controlled clinical trial having included 170 patients. For inclusion, the bronchitis patients had to be in a stable status (no exacerbation since at least three months). The patients received, in double-blind protocol, vectrine, one capsule b.i.d. or placebo, one similar capsule b.i.d. during a period treatment of 21 days. The results of the main evaluation criteria, the global index of efficacy (frequency of the cough + severity of the cough + difficulty in breathing + dyspnea) but also on the intensity and frequency of the cough were statistically significant in favor of vectrine. The safety of the treatment was excellent.
|
Authors | M Aubier, L Berdah |
Journal | Revue des maladies respiratoires
(Rev Mal Respir)
Vol. 16
Issue 4
Pg. 521-8
(Sep 1999)
ISSN: 0761-8425 [Print] France |
Vernacular Title | Etude multicentrique, controlée, en double aveugle, de l'efficacité et de la tolérance de Vectrine (erdostéine) versus placebo dans le traitement de la bronchite chronique hypersecrétante stabilisée. |
PMID | 10549062
(Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Expectorants
- Thioglycolates
- Thiophenes
- erdosteine
|
Topics |
- Administration, Oral
- Adult
- Aged
- Bronchitis
(drug therapy, pathology)
- Chronic Disease
- Double-Blind Method
- Dyspnea
- Expectorants
(administration & dosage, pharmacology, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Severity of Illness Index
- Thioglycolates
(adverse effects, pharmacology, therapeutic use)
- Thiophenes
(adverse effects, pharmacology, therapeutic use)
- Treatment Outcome
|